159 related articles for article (PubMed ID: 11164718)
21. Chemotherapy in patients with progressive, undifferentiated neuroendocrine tumors: a single-center experience.
Deutschbein T; Unger N; Yuece A; Eberhardt W; Gauler T; Lahner H; Mann K; Petersenn S
Horm Metab Res; 2011 Nov; 43(12):838-43. PubMed ID: 21989555
[TBL] [Abstract][Full Text] [Related]
22. Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.
Okuma HS; Iwasa S; Shoji H; Takashima A; Okita N; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y
Anticancer Res; 2014 Sep; 34(9):5037-41. PubMed ID: 25202088
[TBL] [Abstract][Full Text] [Related]
23. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
Hentic O; Hammel P; Couvelard A; Rebours V; Zappa M; Palazzo M; Maire F; Goujon G; Gillet A; Lévy P; Ruszniewski P
Endocr Relat Cancer; 2012 Dec; 19(6):751-7. PubMed ID: 22940375
[TBL] [Abstract][Full Text] [Related]
24. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma.
Schleusener JT; Tazelaar HD; Jung SH; Cha SS; Cera PJ; Myers JL; Creagan ET; Goldberg RM; Marschke RF
Cancer; 1996 Apr; 77(7):1284-91. PubMed ID: 8608504
[TBL] [Abstract][Full Text] [Related]
25. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.
Kulke MH; Wu B; Ryan DP; Enzinger PC; Zhu AX; Clark JW; Earle CC; Michelini A; Fuchs CS
Dig Dis Sci; 2006 Jun; 51(6):1033-8. PubMed ID: 16865563
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy for neuroendocrine tumors: the Beatson Oncology Centre experience.
Hatton MQ; Reed NS
Clin Oncol (R Coll Radiol); 1997; 9(6):385-9. PubMed ID: 9448967
[TBL] [Abstract][Full Text] [Related]
27. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology.
Crippa S; Partelli S; Belfiori G; Palucci M; Muffatti F; Adamenko O; Cardinali L; Doglioni C; Zamboni G; Falconi M
World J Gastroenterol; 2016 Dec; 22(45):9944-9953. PubMed ID: 28018101
[TBL] [Abstract][Full Text] [Related]
28. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
[TBL] [Abstract][Full Text] [Related]
29. Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
Walter T; Malka D; Hentic O; Lombard-Bohas C; Le Malicot K; Smith D; Ferru A; Assenat E; Cadiot G; Lievre A; Kurtz JE; Dahan L; Dubreuil O; Hautefeuille V; Lepere C; Gangloff A; Elhajbi F; Coriat R; Roquin G; Bouarioua N; Granger V; Scoazec JY; Lepage C
Dig Liver Dis; 2018 Feb; 50(2):195-198. PubMed ID: 29258812
[TBL] [Abstract][Full Text] [Related]
30. [Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system].
Pellat A; Wislez M; Svrcek M; Hammel P; Afchain P; André T
Bull Cancer; 2016 Oct; 103(10):880-895. PubMed ID: 27507031
[TBL] [Abstract][Full Text] [Related]
31. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
[TBL] [Abstract][Full Text] [Related]
32. Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination.
Mohamed A; Azmi AS; Asa SL; Tirumani SH; Mahipal A; Cjakrabarti S; Bajor D; Selfridge JE; Kaseb AO
Curr Oncol; 2022 Nov; 29(11):9018-9030. PubMed ID: 36421360
[TBL] [Abstract][Full Text] [Related]
33. Multimodality treatment for poorly differentiated neuroendocrine head and neck carcinomas--a single institution experience.
Görner M; Brasch F; Hirnle P; Gehl HB; Scholtz LU; Wegehenkel K; Sudhoff H
Eur J Cancer Care (Engl); 2013 Sep; 22(5):648-52. PubMed ID: 23701280
[TBL] [Abstract][Full Text] [Related]
34. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
[TBL] [Abstract][Full Text] [Related]
35. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
Li J; Lu M; Lu Z; Li Z; Liu Y; Yang L; Li J; Zhang X; Zhou J; Wang X; Gong J; Gao J; Li Y; Shen L
Oncotarget; 2017 Apr; 8(15):25669-25678. PubMed ID: 27788498
[TBL] [Abstract][Full Text] [Related]
36. The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution.
Kim ST; Ha SY; Lee J; Hong SN; Chang DK; Kim YH; Park YA; Huh JW; Cho YB; Yun SH; Lee WY; Kim HC; Park YS
Medicine (Baltimore); 2016 May; 95(19):e3534. PubMed ID: 27175651
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy in the treatment of neuroendocrine malignant tumors.
Rougier P; Mitry E
Digestion; 2000; 62 Suppl 1():73-8. PubMed ID: 10940691
[TBL] [Abstract][Full Text] [Related]
38. Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma.
Abedallaa N; Tremblay L; Baey C; Fabre D; Planchard D; Pignon JP; Guigay J; Pechoux CL; Soria JC; de Montpreville VT; Besse B
J Thorac Oncol; 2012 Jul; 7(7):1179-83. PubMed ID: 22617247
[TBL] [Abstract][Full Text] [Related]
39. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Welin S; Sorbye H; Sebjornsen S; Knappskog S; Busch C; Oberg K
Cancer; 2011 Oct; 117(20):4617-22. PubMed ID: 21456005
[TBL] [Abstract][Full Text] [Related]
40. First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases.
Patta A; Fakih M
Anticancer Res; 2011 Mar; 31(3):975-8. PubMed ID: 21498724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]